Compare Aterian Inc (ATER) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aterian Inc vs Incyte Corporation — how do they compare? Aterian Inc trades at $0.47 (market cap $5.32M), while Incyte Corporation trades at $120.73 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 4612.8× Aterian Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Aterian Inc nearer its low. Which is the better fit depends on your goals.
| ATER | INCY | |
|---|---|---|
Market Cap | $5.32M | $24.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $1.39 | $129.93 |
52-Week Low | $0.36 | $81.61 |
Enterprise Value | $5.90M | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ATER trades at $0.47, down 2.56% today, with a bearish technical signal despite recent earnings beats. The company shows deteriorating fundamentals with revenue declining from $221M in 2022 to $69M in 2025 and negative net margins. However, positive developments include a pending asset sale expected to return $0.85-$1.14 per share to stockholders, with proxy advisors recommending approval.
The stock faces significant fundamental challenges with persistent losses and negative cash flow, but the proposed asset sale provides potential near-term catalyst. Analyst sentiment is divided with 50% buy ratings. Key risks include execution of the asset sale and ongoing operational losses, while the technical picture remains bearish near-term.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aterian Inc
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
